Welcome
to OHR Pharmaceutical
Ohr Pharmaceutical Inc. (OTCBB:OHRP) is a pharmaceutical company dedicated to the development of first-in-class drugs for underserved therapeutic needs.
OHR is focused on the development of two drugs: OHR/AVR 118 for the treatment of Cancer Cachexia and EVIZON(TM) for the treatment of the wet form of age-related macular degeneration (wet-AMD). Cancer Cachexia, the syndrome of body wasting that affects late-stage cancer patients, is a debilitating condition which adversely affects their quality of life. Wet-AMD is a leading cause of vision loss and blindness in the elderly population. The promise shown by OHR Pharmaceutical's products pipeline offer a new ray of hope to patients suffering from these devastating diseases.
|
|
MISSION STATEMENT Ohr Pharmaceutical's mission is to light the way in bringing new pharmaceuticals to the marketplace for the mitigation of underserved human diseases. |
|
